My understanding is she literally didn’t have enough burns to treat, yes it’s not progressing at this stage.
also, I think fibrosis in keloid is less than established / surgical scars. I suspect it is a redo - but with almost guaranteed results imo.
the god thing is that the results will support the new scarring trial, and they support myelofibrosis trail, and we may have never even looked at scarring if Fiona didn’t do it, and it cost us very little.
we don’t have enough $ to do everything, but if we can licence myelo for say $500m upfront after our final data, we will have the share price and the cash to do wanted we want, including running our own keloid trial.
fingers crossed
SNT Price at posting:
8.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)